On the Frontlines of Non-Small Cell Lung Cancer

1-5 of 5

• 

  RestartResume

  Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC

  RestartResume

  Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC

  On the Frontlines of Non-Small Cell Lung Cancer

  Neoadjuvant and Adjuvant Therapy in Early-Stage NSCLC

  Steve Jackson, PharmD; David Carbone, MD, PhD

  • 

    

    Steve Jackson, PharmD

  • 

    

    David Carbone, MD, PhD

• 

  RestartResume

  Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer

  RestartResume

  Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer

  On the Frontlines of Non-Small Cell Lung Cancer

  Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer

  Ryan Quigley; Alexander Drilon, MD

  • 

    

    Ryan Quigley

  • 

    

    Alexander Drilon, MD

• 

  RestartResume

  Molecular Testing in Advanced Non-Small Cell Lung Cancer

  RestartResume

  Molecular Testing in Advanced Non-Small Cell Lung Cancer

  On the Frontlines of Non-Small Cell Lung Cancer

  Molecular Testing in Advanced Non-Small Cell Lung Cancer

  Alexandria May, PharmD, BCPS; Timothy F. Burns, MD, PhD

  • 

    

    Alexandria May, PharmD, BCPS

  • 

    

    Timothy F. Burns, MD, PhD

• 

  RestartResume

  Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

  RestartResume

  Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

  Project Oncology®

  Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

  Jacob Sands, MD; Aakesh Desai, MD, MPH

  • 

    

    Jacob Sands, MD

  • 

    

    Aakesh Desai, MD, MPH

• 

  RestartResume

  NSCLC Care: Evaluating Durvalumab in the First-Line Setting

  RestartResume

  NSCLC Care: Evaluating Durvalumab in the First-Line Setting

  Project Oncology®

  NSCLC Care: Evaluating Durvalumab in the First-Line Setting

  Jacob Sands, MD; Liza Villaruz, MD

  • 

    

    Jacob Sands, MD

  • 

    

    Liza Villaruz, MD